News | March 19, 2012

Cameron Health’s Subcutaneous ICD Scheduled for FDA Panel Review in April


March 19, 2012 - Cameron Health Inc. announced today that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel will review the premarket approval (PMA) application of the S-ICD (Subcutaneous-Implantable Cardioverter Defibrillator) system  April 26, 2012.

“The FDA advisory committee meeting represents a significant step towards obtaining U.S. approval of the S-ICD System,” said Kevin Hykes, Cameron Health’s president and CEO. “We look forward to the opportunity to discuss the safety and efficacy of the S-ICD system with the FDA review team. Our clinical data will demonstrate that the S-ICD System is a valuable new treatment option for patients at risk of sudden cardiac arrest.”

The FDA advisory panel will review clinical data on the safety and efficacy of the S-ICD System including the results of a pivotal investigational device exemption (IDE) clinical study of 330 patients at risk of SCA. The PMA application was submitted to the FDA in December 2011.

On March 8, Boston Scientific Corp. announced that it would exercise its option to acquire Cameron Health Inc. Closing of the transaction is subject to customary conditions, including relevant antitrust clearance, and is expected to occur in the second or third quarter of 2012.

To see a video of how the system is implanted, click here.

For more information: www.cameronhealth.com


Related Content

News | Implantable Cardioverter Defibrillator (ICD)

August 29, 2022 — Medtronic plc announced that its investigational EV ICD System – a first-of-its-kind defibrillator ...

Home August 29, 2022
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 18, 2022 — A first-in-human multicenter trial involving Mayo Clinic used a new ablation technique for patients ...

Home August 18, 2022
Home
News | Implantable Cardioverter Defibrillator (ICD)

July 21, 2022 — The global automated external defibrillators market size was valued at USD 717 million in 2021. It is ...

Home July 22, 2022
Home
News | Implantable Cardioverter Defibrillator (ICD)

June 10, 2022 — Setting a lower price to enter a competitive market with established brand leaders is a common ...

Home June 10, 2022
Home
News | Implantable Cardioverter Defibrillator (ICD)
May 2, 2022 – High-risk patients who need defibrillators to prevent cardiac arrest can experience fewer complications ...
Home May 02, 2022
Home
News | Implantable Cardioverter Defibrillator (ICD)
February 14, 2022 — Philips, a global leader in health technology, is supporting the American Heart Association’s multi ...
Home February 14, 2022
Home
Feature | Implantable Cardioverter Defibrillator (ICD) | By Dave Fornell, Editor

February 2, 2020 — The U.S. Food and Drug Administration (FDA) has identified a recent recall of the Boston Scientific ...

Home February 02, 2021
Home
News | Implantable Cardioverter Defibrillator (ICD)

January 8, 2020 — A new study published this week in HeartRhythm, the journal of the Heart Rhythm Society (HRS), found ...

Home January 08, 2021
Home
News | Implantable Cardioverter Defibrillator (ICD)

May 8, 2020 — Final results from the UNTOUCHED study of the Emblem Subcutaneous Implantable Defibrillator (S-ICD) System ...

Home May 08, 2020
Home
Subscribe Now